Date: 2015-06-09
Type of information: Nomination
Compound:
Company: Amag Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 9, 2015, Amag Pharmaceuticals announced the appointment of Aaron Pelta as vice president of business development and transactions, reporting to Melissa Klug, senior vice president of business development and strategy. Mr. Pelta comes to Amag with more than 15 years of experience in corporate and business development, commercialization, strategy and operations, having executed multiple mergers, acquisitions and licensing deals. Prior to joining Amag, Mr. Pelta served in various positions of increasing responsibility in the business development and commercial groups at Cubist Pharmaceuticals from 2004 to 2015, including senior director, business development, where he led the transaction teams responsible for the acquisitions of Optimer Pharmaceuticals and Adolor Pharmaceuticals. Most recently, Mr. Pelta served as the brand lead for DIFICID, where he led the commercial re-launch of the product. Prior to Cubist, he worked in the commercial analytics group at Biogen, where he supported the sales and marketing teams in launching Amevive. He also served in research & development and engineering roles at Gamera Bioscience and Praxair, Inc. Mr. Pelta holds a bachelor\'s of science in chemical engineering from Tufts University and a master\'s of business administration from the Tuck School of Business at Dartmouth College.
Financial terms:
Latest news:
